Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AGC Biologics Launches BravoAAV and ProntoLVV Platforms for CGTs | Contract Pharma

What are you searching for?

Sign in
Breaking News

AGC Biologics Launches BravoAAV and ProntoLVV Platforms for CGTs

Designed to provide flexible and accelerated vector development and manufacturing for cell and gene therapy programs.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AGC Biologics, a global biopharmaceutical CDMO, launched its BravoAAV and ProntoLVV viral vector platforms. The new platforms leverage the company’s Lentiviral vector (LVV) and Adeno-Associated Viral vector (AAV) development, manufacturing and analytical experience to offer fast, efficient and reproducible clinical and commercial GMP production and release. The company’s process and capsid-specific platform methods aim to accelerate development timelines, delivering GMP product in nine months.
 
The BravoAAV and ProntoLVV platforms have production at different scales in suspension up to 2,000 L and adhesion up to 750 L, and include prequalified scale-down models simplifying and accelerating the path to commercialization.
 
The AAV and LVV platforms include in-network plasmid DNA (pDNA) supplies (high-quality and GMP-grade), all major testing performed in-house and the use of cell factories and fixed bed bioreactor for adherent protocols, and wave and stirrer bioreactors for suspension. BravoAAV and ProntoLVV also include a comprehensive set of analytical methods pre-qualified for clinical application and ready to validate for commercial purposes, and a templated material approach to help support regulatory steps and approvals. 
 
BravoAAV and ProntoLVV are designed by the scientists at the AGC Biologics Milan site, a group with 30 years of experience building custom vector programs that scale to commercial levels and meet global regulatory standards. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics